OLD Category: Oncology

January 24, 2024 / Acta Neuropathol

  • Gödicke S, Kresbach C, Ehlert M, Obrecht D, Altendorf L, Hack K, von Hoff K, Carén H, Melcher V, Kerl K, Englinger B, Filbin M, Pajtler KW, Gojo J, Pietsch T, Rutkowski S, Schüller U
Posterior fossa type A (PF-EPN-A, PFA) ependymoma are aggressive tumors that mainly affect children and have a poor prognosis. Histopathology shows significant intratumoral heterogeneity, ranging from loose tissue to often…
January 18, 2024 / JID Innovations

  • Eddy K, Kajal Gupta, Mohamad Naser Eddin, Christina Marinaro, Sanjana Putta, John Sauer, Anna Chaly, Katie B. Freeman, Jeffrey C. Pelletier, Anna Fateeva, Philip Furmanski, Ann W. Silk, Allen B. Reitz, Andrew Zloza, Suzie Chen
Previous work done by our lab described the use of an immunocompetent spontaneous melanoma-prone mouse model, TGS (TG-3/SKH-1) to evaluate treatment outcomes using inhibitors of glutamatergic signaling and immune checkpoint…
January 17, 2024 / J Pathol

  • Duan S, Sawyer TW, Witten BL, Song H, Else T, Merchant JL
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous malignancies that arise from complex cellular interactions within the tissue microenvironment. Here, we sought to decipher tumor-derived signals from the surrounding microenvironment by applying…
January 16, 2024 / Int J Mol Sci

  • Kwon MJ, Park HY, Lim H, Son IT, Kim MJ, Kim NY, Kim MJ, Nam ES, Cho SJ, Bang WJ, Kang HS
There is a debate regarding the prediction of lymph node metastasis (LNM) in pedunculated T1 colorectal cancer (CRC). In this study with four cases of pedunculated T1 CRCs, we aimed…
January 15, 2024 / Life (Basel)

  • Suwatthanarak T, Thanormjit K, Suwatthanarak T, Acharayothin O, Methasate A, Chinswangwatanakul V, Tanjak P
Stage 4 colon cancer (CC) presents a significant global health challenge due to its poor prognosis and limited treatment options. Tetraspanins, the transmembrane proteins involved in crucial cancer processes, have…
January 9, 2024 / JCI Insight

  • Ihle CL, Straign DM, Canari JA, Torkko KC, Zolman KL, Smith EE, Owens P
Metastatic breast cancer (mBC) tissue in bone was systematically profiled to define the composition of the tumor microenvironment. Gene expression identified a high myeloid signature of patients with improved survival…
January 2, 2024 / Nat Cancer

  • Li Z, Pai R, Gupta S, … Chow PKH, Ginhoux F, Sharma A
Onco-fetal reprogramming of the tumor ecosystem induces fetal developmental signatures in the tumor microenvironment, leading to immunosuppressive features. Here, we employed single-cell RNA sequencing, spatial transcriptomics and bulk RNA sequencing…
December 22, 2023 / Clin Transl Med

  • Uddin MH, Al‐Hallak MN, Khan HY, Aboukameel A, Li Y, Bannoura SF, Dyson G, Kim S, Mzannar Y, Azar I, Odisho T, Mohamed A, Landesman Y, Kim S, Beydoun R, Mohammad RM, Philip PA, Shields AF, Azmi AS
Background: The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac) necessitating the need for a more effective treatment…
December 21, 2023 / Mater Today Bio

  • Bakkalci D, Georgina Al-Badri, Wei Yang, Andy Nam, Yan Liang, Syed Ali Khurram, Susan Heavey, Stefano Fedele, Umber Cheema
Stromal cells are key components of the tumour microenvironment (TME) and their incorporation into 3D engineered tumour-stroma models is essential for tumour mimicry. By engineering tumouroids with distinct tumour and…
December 18, 2023 / Cancers (Basel)

  • Qurat-Ul-Ain, Frei NF, Khoshiwal AM, Stougie P, Odze R, Camilleri-Broet S, Ferri L, Duits LC, Bergman J, Stachler MD
Characterization of the Barrett's esophagus (BE) microenvironment in patients with a known progression status, to determine how it may influence BE progression to esophageal adenocarcinoma (EAC), has been understudied, hindering…
December 12, 2023 / Eur Urol

  • Beckabir W, Wobker SE, Damrauer JS, Midkiff B, De la Cruz G, Makarov V, Flick L, Woodcock MG, Grivas P, Bjurlin MA, Harrison MR, Vincent BG, Rose TL, Gupta S, Kim WY, Milowsky MI
BACKGROUND: Platinum-based neoadjuvant chemotherapy (NAC) is standard for patients with muscle-invasive bladder cancer (MIBC). Pathologic response (complete: ypT0N0 and partial:
December 12, 2023 / Cancer Cell

  • Sun Y, Wu P, Zhang Z, Wang Z, Zhou K, Song M, Ji Y, Zang F, Lou L, Rao K, Wang P, Gu Y, Gu J, Lu B, Chen L, Pan X, Zhao X, Peng L, Liu D, Chen X, Wu K, Lin P, Wu L, Su Y, Du M, Hou Y, Yang X, Qiu S, Shi Y, Sun H, Zhou J, Huang X, Peng DH, Zhang L, Fan J
Comprehensive molecular analyses of metastatic hepatocellular carcinoma (HCC) are lacking. Here, we generate multi-omic profiling of 257 primary and 176 metastatic regions from 182 HCC patients. Primary tumors rich in…